Events Inpatient Labelling 
Pharmacy Joe
MAY 1, 2024
Subscribe on iTunes , Android , or Stitcher The label of “penicillin allergic” usually sticks to a patient’s medical record forever. A 50 y/o male with an SSTI had an unknown allergy to penicillin, received a single dose of ceftriaxone in the ED and was then switched to piperacillin-tazobactam as an inpatient.
Pharmacy Joe
OCTOBER 11, 2020
In this episode, I’ll discuss how to predict the pharmacotherapy needs of your patient and team during an inpatient medical emergency. This is when you do regular pharmacist things like drawing up and labeling medications, and calculating doses. This work is valuable because it frees a nurse up to be hands-on with a patient.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Joe
OCTOBER 22, 2023
The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.
Pharmacy Joe
OCTOBER 22, 2023
The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.
Pharmacy Joe
NOVEMBER 29, 2020
To improve the data available in this patient population, investigators in Brazil completed a multicenter, randomized, open-label, noninferiority trial with 1000 patients comparing rivaroxaban with warfarin for patients with atrial fibrillation and a bioprosthetic mitral valve.
Pharmacy Joe
AUGUST 21, 2022
Recently published in Lancet was a non-inferiority, open-label, multicentre, randomized trial that sought to clarify the safety of early antibiotic discontinuation in hematology patients with fever of unknown origin during chemotherapy-induced neutropenia.
Pharmacy Joe
AUGUST 21, 2022
Recently published in Lancet was a non-inferiority, open-label, multicentre, randomized trial that sought to clarify the safety of early antibiotic discontinuation in hematology patients with fever of unknown origin during chemotherapy-induced neutropenia.
Expert insights. Personalized for you.
98 
Let's personalize your content